In a recent phase 3 randomized clinical trial of men with low-risk prostate cancer (PC), treatment with hyprofractionated radiotherapy (HRT) was shown to be noninferior to conventional radiotherapy (CRT) in terms of disease-free survival with no differences in prostate cancer-specific and general quality of life (QOL), as well as in anxiety and depression. QOL was assessed using the Expanded Prostate Index Composite questionnaire measuring bowel, urinary, sexual, and hormonal domains; the 25-item Hopkins System Checklist measuring anxiety and depression, and the EuroQol-5 Dimension questionnaire measuring global QOL. All data were collected at baseline and 6, 12, 24, and 60 months. Participants were randomly assigned to CRT (73.8 Gy in 41 fractions over 8.2 weeks) or to HRT (70 Hy in 28 fractions over 5.6 weeks). Researchers found:

• 962 patients (mean age 66.6 years) were eligible.
• No statistically significant differences with regards to baseline characteristics nor any of the QOL baseline domains were measured between arms.
• There were no differences in change score between arms with respect to any of the Expanded Prostate Index Composite questionnaire domain scores expect at 12 months when the HRT arm had a larger decline than the CRT arm in the bowel domain.